Circulating tumour DNA (ctDNA) has shown remarkable prognostic value for OS and RFS in very small cohorts of patients with early-stage CC.12–14 Lu et al. suggested that the combination of post-operative serum CEA levels assessment and persistent post-operative circulating tumour cells detection is prognostic predictor of early relapse in stage II–III CC patients.15 This evidence concerns the gene CEACAM5 and neoplasm.